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METHODS OF DELAYING DEVELOPMENT 
OF CEA-ASSOCIATED TUMORS USING 
ANTI-IDIOTYPE ANTIBODY 3H1 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of US. patent applica 
tion Ser. No. 10/162,396, noW abandoned, Which is a con 
tinuation of US. patent application Ser. No. 09/844,736, 
noW abandoned, Which is a continuation of US. patent 
application Ser. No. 08/838,692, now US. Pat. No. 6,235, 
280, Which claims the bene?t of US. Provisional application 
60/044,455, noW expired. 
STATEMENT OF RIGHTS TO INVENTIONS 
MADE UNDER FEDERALLY SPONSORED 
RESEARCH 
(Not Applicable) 
FIELD OF THE INVENTION 
This invention relates to uses of anti-idiotype antibodies. 
More particularly, it relates to methods of treatment using 
anti-idiotype antibody 3H1, in Which administration of 3H1 
delays CEA-associated tumor development. 
BACKGROUND OF THE INVENTION 
In spite of extensive medical research and numerous 
advances, cancer remains the second leading cause of death 
in the United States. Colorectal cancer is the third most 
common cancer and the second leading cause of cancer 
deaths. While the traditional modes of therapy, such as 
surgery, radiotherapy and chemotherapy, are Widely used 
and are in many instances successfull, the still existing high 
death rate from cancers such as colorectal compels the need 
for alternative or additional modes of therapy. 
Even if a patient responds to traditional modes of therapy, 
there is often a signi?cant risk of recurrence of the disease. 
This is especially true if the disease has spread When 
diagnosed. Even after “successful” treatment, in Which a 
remission is observed, a patient can have high risk of 
recurrence, and can only “Watch and, Wait.” There are 
presently no further courses of action to delay or prevent 
recurrence. 
One approach to cancer therapy has been immunotherapy. 
HoWever, immunotherapy of human cancer using tumor 
cells or tumor-derived vaccines has been disappointing for 
several reasons. It has been consistently difficult to obtain 
large quantities or puri?ed tumor-associated antigens Which 
are often chemically ill-de?ned and difficult to purify. In 
addition, there remains the problem of immunobiological 
response potential against tumor antigens, or in other Words, 
the question of Whether a cancer patient can effectively 
mount an immune response against his or her tumor. Tumor 
associated antigens (TAA) are often a part of “self” and 
usually evoke a very poor immune response in a tumor 
bearing host due to tolerance to the antigens, such as T 
cell-mediated suppression. Moreover, cancer patients tend to 
be immunosuppressed and only respond to certain T-depen 
dent antigens. 
Immunobiologists have learned that a poor antigen (in 
terms of eliciting an immune response) can be turned into a 
strong antigen by clanging the molecular environment. 
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Changes of hapten carrier alloW T cell helper cells to 
become active, making the overall immune response stron 
ger. Thus, changing the carrier can also turn a tolerogenic 
antigen into an effective antigen. McBridge et al. (1986) Br. 
J. Cancer 53:707. Often the immunological status of a 
cancer patient is suppressed such that the patient is only able 
to respond to certain T-dependent antigens and not to other 
antigen forms. From these considerations, it Would make 
sense to introduce molecular changes into the tumor asso 
ciated antigens before using them as vaccines. Unfortu 
nately, this is impossible to accomplish for most tumor 
antigens, because they are not Well de?ned and are very hard 
to purify. 
The netWork hypothesis of Lindemann ((1973) Ann. 
Immunol. 124:171-184) and Jeme ((1974) Ann. Immunol. 
125:373-389) offers an elegant approach to transform 
epitope structures into idiotypic determinants expressed on 
the surface of antibodies. According to the netWork concept, 
immunization With a given tumor-associated antigen Will 
generate production of antibodies against this tumor-asso 
ciated antigen, termed Ab1; this Ab1 is then used to generate 
a series of anti-idiotype antibodies against the Ab1 termed 
Ab2. Some of these Ab2 molecules can effectively mimic 
the three-dimensional structure of the tumor-associated anti 
gen identi?ed by the Ab1. These particular anti-idiotypes 
called Ab2[3 ?t into the paratopes of Ab1, and express the 
internal image of the tumor-associated antigen. The Ab2[3 
can induce speci?c immune responses similar to those 
induced by the original tumor-associated antigen and can, 
therefore, be used as surrogate tumor-associated antigens. 
Immunization With Ab2[3 can lead to the generation of 
anti-anti-idiotype antibodies (Ab3) that recogniZe the cor 
responding original tumor associated antigen identi?ed by 
Ab1. Because of this Ab1-like reactivity, the Ab3 is also 
called Ab1' to indicate that it might differ in its other 
idiotopes from Ab1. 
A potentially promising approach to cancer treatment is 
immunotherapy employing anti-idiotype antibodies. In this 
form of therapy, an antibody mimicking an epitope of a 
tumor -associated protein is administered in an effort to 
stimulate the patient’s immune system against the tumor, via 
the tumor-associated protein. WO 91/11465 describes meth 
ods of stimulating an immune response in a human against 
malignant cells or an infectious agent using primate anti 
idiotype antibodies. HoWever, not all anti-idiotype antibod 
ies can be used in therapeutic regimens against tumors. First, 
only a fraction of antibodies raised against an Ab1 are 
limited in their reactivity to the paratope of Ab1 (i.e., are 
non-reactive against features shared With other potential 
antibodies in the host). Second, anti-idiotype antibodies are 
not necessarily immunogenic. Third, even if an anti-idiotype 
elicits an immune response, only a fraction of these immu 
nogenic anti-idiotypes elicit an immune response against the 
tumor antigen and not against other antigens With less 
speci?city. Moreover, since different cancers have Widely 
varying molecular and clinical characteristics, it has been 
suggested that anti-idiotype therapy should be evaluated on 
a case by case basis, in terms of tumor origin and antigens 
expressed. 
Anti-Id monoclonal antibodies structurally resembling 
tumor-associated antigens have been used as antigen sub 
stitutes in cancer patients. Herlyn et al. (1987) Proc. Natl. 
Acad. Sci. USA. 84:8055-8059; Mittleman et al. (1992) 
Proc. Natl. Acad. Sci. USA. 891466-470; Chatterjee et al. 
(1993)Ann. NYAcad. Sci. 690:376-278. All ofthese studies 
Were conducted With patients having advanced disease. 
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Based on the observed immune response in at least some of 
the patients, it has been proposed that the anti-Id provides a 
partial analog of the tumor-associated antigen in an immu 
nogenic context. 
Carcinoembryonic antigen (CEA) is a 180,000-kiloDal 
ton glycoprotein tumor-associated antigen present on endo 
dermally-derived neoplasms of the gastrointestinal tract, 
such as colorectal and pancreatic cancer, as Well as other 
adenocarcinomas such as breast and lung cancers. A major 
ity of colorectal, gastric, pancreatic as Well as breast and 
non-small cell lung carcinomas are associated With CEA. 
CEAis also found in the digestive organs of the human fetus. 
Circulating CEA can be detected in the great majority of 
patients With CEA-positive tumors. Speci?c monoclonal 
antibodies have been raised against CEA and some have 
been radiolabeled for diagnostic and clinical studies. Hansen 
et al. (1993) Cancer 71:3478-3485; Karoki et al. (1992) 
Hibridoma 11:391-407; Goldenberg (1993) Am. J. Med. 
94:297-312. As With most tumor-associated antigens Which 
are seen as self-antigens by the immune system, cancer 
patients are immunologically “tolerant” to CEA, likely 
related to its oncofetal origin. This has rendered immuno 
therapy based on CEA virtually impossible. Studies to date 
on patients With CEA-positive tumors have not demon 
strated the ability to generate immunity to CEA. 
CEA nonetheless is an excellent tumor-associated antigen 
for active immunotherapy With anti-idiotype antibody for 
several reasons. CEA is typically present at high levels on 
the tumor cell surface. CEA is also one of the most Well 
characteriZed antigens, as its gene sequence is knoWn and its 
three dimensional structures have been identi?ed. CEA is a 
member of the immunoglobulin supergene family located on 
chromosome 19 Which is thought to be involved in cell-cell 
interactions. 
Inasmuch as some of the epitopes on CEA are shared by 
normal tissues, immunization With intact CEA molecule 
might trigger potentially harmful autoimmune reactions. An 
immune reaction against a tumor associated epitope, on the 
other hand, Would be desirable. A number of investigators 
have generated anti-idiotype antibodies in rats, mice, 
baboons and humans that mimic CEA. See, e.g., Hinoda et 
al. (1995) Tumor Biol. 16:48-55; Losman et al. (1994) Int. J. 
Canoer 56:580-584; Irvine et al. (1993) Cancer Immunol. 
Immunolher. 36:281-292. HoWever, given the siZe of CEA 
(and likely numerous epitopes), and the fact that CEA is 
expressed on some normal tissues, it Was not knoWn Whether 
anti-idiotype antibodies Would be effective in eliciting an 
anti-CEA response that effects anti-tumor immunity. 
CEA-associated tumors, such as carcinomas of the gas 
trointestinal tract, are often not curable by standard thera 
pies. Even if a patient responds to traditional therapy, there 
is often a signi?cant risk of recurrence. Thus, neW thera 
peutic approaches for this disease are needed. The present 
invention overcomes the de?ciencies in the prior art by 
providing methods of treatment for CEA-associated tumors 
using monoclonal anti-idiotype antibody (3H1) Which 
escapes immune tolerance and induces an anti-CEA immune 
response. 
All references cited herein are incorporated by reference 
in their entirety. 
SUMMARY OF THE INVENTION 
The present invention is directed to therapeutic uses of the 
anti-idiotype antibody 3H1. 
Accordingly, one aspect of the invention is methods of 
delaying development of CEA-associated tumors an indi 
vidual having a loW tumor burden, particularly high risk 
individuals. These methods include administration of an 
effective amount of anti-idiotype antibody 3H1 to the indi 
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vidual. In another aspect, the invention further includes 
administration of 3H1 With an adjuvant. 
In another aspect, methods are provided for treatment of 
a CEA-associated tumor in an individual With a loW tumor 
burden Which entail administering an effective amount of 
3H1 to the individual. 
In another aspect, methods are provided for treatment of 
a CEA-associated tumor in an individual having a loW tumor 
burden and having a level of circulating CEA less than about 
50 ng/ml, Which entail administration of an effective amount 
of 3H1 to the individual. 
In another aspect, 3H1 is used to treat a CEA-associated 
tumor of colon or colorectal origin. These methods include 
administration of an effective amount of 5-?uorouracil, 
levamisole hydrochloride or leucovorin calcium, and an 
effective amount of 3H1 to an individual. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1(A)-(D) are graphs depicting the generation of an 
immune response in mice inoculated With 3H1. FIG. 1(A) 
depicts an assay of anti-3H1 antibody; FIG. 1(B) depicts an 
assay of anti-CEA antibody; FIGS. 1(C) and (D) depict T 
cell proliferative response (solid bar denotes CEA; open bar 
denotes 3H1). N indicates PBS vaccinated mice. 
FIG. 2 is a series of graphs depicting the increased 
survival after tumor challenge in mice inoculated With 3H1. 
Survival Was measured after six immuniZations With 3H1. 
Circles denote challenge With MC38 (CEA negative) cells; 
squares denote challenge With MC38cea (CEA positive) 
cells. FIG. 2(A) shoWs percent survival of mice immuniZed 
With 3H1-KLH. FIG. 2(B) shoWs percent survival of mice 
immuniZed With isotype matched anti-idiotype antibody 
11D10 conjugated to KLH. FIG. 2(C) shoWs percent sur 
vival of mice immuniZed With PBS. 
FIG. 3 is a graph depicting inhibition of binding of Ab1 
(8019) to Ab2 (3H1) the presence of 6 high risk patients’ 
sera (after administration of 3H1). Squares With dots in the 
center denote patient #1; solid diamonds denote patient #2; 
solid squares With open center denote patient #3; open 
diamonds denote patient #4; solid squares denote patient #5; 
open squares denote patient #6. Patients #1 -3 Were receiving 
?uorouracil (5-FU) and levamisole concurrently With 3H1. 
FIG. 4 is a bar graph depicting antibody dependent 
cellular cytotoxicity (ADCC) in the sera of 6 high risk 
patients receiving 3H1. The ?rst through sixth bars represent 
patient numbers 1 through 6, respectively. 
FIG. 5 is a bar graph depicting ADCC in the sera of 2 high 
risk patients receiving 3H1. In both halves of the graph, 
effector cells from patient #1 Were used Ab3 Was from 
patient #1 (left side) or patient #2 (right side). 
FIG. 6 depicts the cDNA sequence (SEQ ID NO:3; FIG. 
6A) and the amino acid sequence (SEQ ID NO:4; FIG. 6B) 
of the light chain variable region of 3H1 and adjoining 
residues. 
FIG. 7 depicts the cDNA sequence (SEQ ID NO:5; FIG. 
7A); and the amino acid sequence (SEQ ID NO:6; FIG. 7B) 
of the heavy chain variable region of 3H1 and adjoining 
residues. 
FIGS. 8(A) and (B) are graphs depicting detection of an 
immune response to 3H1 in mice at varying dilutions of sera. 
FIG. 8(A) depicts an assay of anti-3H1 antibody; FIG. 8(B) 
depicts an assay of anti-CEA (Ab1') antibody. In FIG. 8(A), 
Ab2-C1 denotes control antibody 1A7; Ab2-C2 denotes 
control plates coated With 3H1 but serum samples Were from 
mice immuniZed 5 times With 1A7-KLH conjugate. Other 
lines in the graph indicate different numbers of immuniZa 
tions (3x; 5x; 6x; 7x) and pre-immune serum. In FIG. 8(B), 
absorbance Was measured before and after 3 (“3x”), 5 
(“5x”), and 7 (“7”) Weekly injections. 
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FIGS. 9(A)-(F) are tracings of How cytometric analysis of 
Ab1' generated in mice by immunization With 3H1. FIGS. 
9(A)-(C) show incubation of MC-38-cea cells (A, sera from 
mice before and after six immunizations With 3H1-KLH 
conjugate; B, PBS and monoclonal anti-CEA antibody 8019; 
C, sera from mice before and after six immunizations With 
isotype-matched unrelated anti-idiotype antibody 1A7 
KLH. FIGS. 9(D)-(F) shoW incubation of MC-38 cells (D, 
before and after six immunizations With 3H1-KLH conju 
gate; E, PBS and 8019; F, before and after six immunizations 
With 1A7-KLH). 
FIG. 10 is a bar graph depicting ADCC by serum from 
mice immunized With 3H1. Diagonally hatched bar denotes 
3H1 (1:5); open bar denotes 3H1 (1:10); cross hatched bar 
denotes PBS (1:5); vertically hatched bar denotes PBS 
(1:10). 
DETAILED DESCRIPTION OF THE 
INVENTION 
We have discovered that administration of 3H1 increases 
survival in mice having CEA-positive tumors and protects 
mice from a tumor challenge. We have also found that 
administration of the anti-idiotype antibody 3H1 in humans 
Who have had CEA-associated tumors successfully treated 
(i.e., no detectable metastasis or disease) elicits a CEA 
speci?c immune response. Importantly, We have also dis 
covered that administration of 3H1 to individuals having 
loW tumor burden Who are at high risk of recurrence of 
CEA-associated tumors remain asymptomatic longer than 
Would be statistically expected. In particular, one patient 
With virtually a 100% risk of recurrence Within six months 
remained asymptomatic for over tWenty months after receiv 
ing 3H1. We believe that administration of 3H1 can reduce 
the risk of CEA-associated tumor occurrence, particularly in 
high risk individuals in the adjuvant setting. 
3H1 is a murine monoclonal anti-idiotype (Id) antibody 
(Ab2) Which induces a speci?c immune response against a 
distinct and speci?c epitope of carcinoembryonic antigen 
(CEA), a tumor-associated antigen. This epitope is unique to 
CEA and is not present on other CEA-related loWer molecu 
lar Weight members of this family Which are also found on 
normal tissues. The antigenic determinant as de?ned by the 
monoclonal antibody 8019 (Ab1) against Which 3H1 Was 
raised is absent on normal adult tissues as evidenced by 
immunoperoxidase staining and hematopoietic analysis. The 
generation and characterization of 3H1 has been described 
in commonly oWned US. Pat. No. 5,977,315, as Well as the 
DNA sequences encoding the variable regions of 3H1 (light 
and heavy chains). A hybridoma that produces 3H1 has been 
deposited With the American Type Culture Collection 
(ATCC), 12301 ParklaWn Drive, Rockville, Md., USA. 
20852 on Dec. 15, 1995, under the provisions of the Budap 
est Treaty for the International Recognition of the Deposit of 
Microorganisms for the Purposes of Patent Procedure. It Was 
accorded Accession Number HB12003. 
In a previous Phase I clinical trial, 12 colorectal cancer 
patients having advanced CEA-associated disease (Who had 
failed all previous therapy and still had high tumor burden) 
Were administered 3H1. Bhattacharya-Chatterjee et al. 
(1994) XVIInZernaZ’l Cancer Congress pp. 495-498. Nine of 
the 12 patients developed high titers of speci?c anti-anti-Id 
(Ab3) antibodies that Were capable of inhibiting binding of 
Ab1 to Ab2 or CEA. All nine of these patients also generated 
speci?c anti-CEA antibodies Which reacted With puri?ed 
CEA and shoWed the identical immunostaining patterns as 
Ab1 on autologous and allogeneic colonic tumors. Further 
more, 7 of the 12 patients demonstrated Id-speci?c T cell 
proliferative responses. Four of these seven patients also 
shoWed T cell proliferation in the presence of CEA. Toxicity 
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Was minimal for all 12 patients. HoWever, all of these 
patients displayed normal disease progression. 
De?nitions 
As used herein, the terms “3H1,” “3H1 antibody” and 
“3H1 monoclonal anti-idiotype antibody” are used inter 
changeably to refer to an anti-idiotype antibody (Ab2) Which 
contains an epitope that at least partially resembles a distinct 
and speci?c epitope of the 180,000 M.W. carcinoembryonic 
antigen (CEA) primarily expressed in high density by 
human pancreatic and colonic tumor cells. The generation 
and characterization of 3H1 is described in commonly 
oWned patent application Ser. No. 08/579,940. Di?ferent 
biological functions are associated With 3H1, including, but 
not limited to, binding to Ab1 (8019) and/or Ab3 and an 
ability to induce an immune response (humoral and/or 
cellular) against CEA in mice, rabbits, monkeys, and 
humans With advanced CEA-associated disease, particularly 
CEA-associated tumors, as Well as humans With a history of 
CEA-associated disease but no detectable disease. 
A “CEA-associated tumor” is one that contains a CEA 
antigen, especially expressed on the tumor cell surface. 
Methods of detecting CEA are knoWn in the art and 
examples are described herein. 
As used herein, “treatment” is an approach for obtaining 
bene?cial or desired clinical results. For purposes of this 
invention, bene?cial or desired clinical results include, but 
are not limited to, one or more of the folloWing: alleviation 
of symptoms, diminishment of extent of disease, stabilized 
(i.e., not Worsening) state of disease, preventing spread (i.e., 
metastasis) of disease, preventing occurrence or recurrence 
of disease, delay or sloWing of disease progression, amelio 
ration of the disease state, and remission (Whether partial or 
total). Also encompassed by “treatment” is a reduction of 
pathological consequences of a CEA-associated tumor(s). 
As used herein, “delaying” development of a CEA-asso 
ciated tumor(s) means to defer, hinder, sloW, retard, stabi 
lize, and/or postpone development of the disease. This delay 
can be of varying lengths of time, depending on the history 
of the disease and/or individual being treated. As is evident 
to one skilled in the art, a suf?cient or signi?cant delay can, 
in effect, encompass prevention, in that the individual does 
not develop the disease. A method that “delays” develop 
ment of CEA-associated tumor(s) is a method that reduces 
probability of disease development in a given time frame 
and/or reduces extent of the disease in a given time frame, 
When compared to not using the method. Such comparisons 
are typically based on clinical studies, using a statistically 
signi?cant number of subjects. 
“Development” of CEA-associated tumor(s) means pro 
gression of the tumor(s). Tumor development can be detect 
able using standard clinical techniques as described herein. 
HoWever, development also refers to disease progression 
that may be undetectable. For purposes of this invention, 
progression refers to the biological course of the disease 
state, in this case (i.e., CEA-associated tumors) cell division 
and/or metastasis of the CEA-associated tumor. “Develop 
ment” includes occurrence, recurrence, and onset. As used 
herein “onset” or “occurrence” of CEA-associated disease 
includes initial onset and and/or recurrence. 
As used herein, “loW tumor burden” means that an 
individual does not have advanced CEA-associated 
tumor(s). “Advanced” CEA-associated tumor(s) means that 
there is detectable metastasis, that is, detectable tumor 
masses at sites other than the primary site of the tumor. 
Tumor masses are preferably detected by imaging tech 
niques knoWn in the art such as X-ray, CT scan, or MRI. 
“Advanced” disease does not include lymph node involve 
ment. As the term indicates, “loW tumor burden” indicates a 
lesser extent of disease than the maximum, or end-stage 
levels that have been described for CEA-associated tumors. 
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It is understood that “loW tumor burden” also includes no 
detectable tumor. Examples of loW tumor burden categories 
are provided beloW. 
As used herein, a “high risk” individual is an individual 
Who is at major risk of development of CEA-associated 
tumors. A “high risk” individual may or may not have 
detectable disease, and may or may not have displayed 
detectable disease prior to the treatment methods described 
herein. “High risk” denotes that an individual has one or 
more so-called risk factors, Which are measurable param 
eters that correlate With development of CEA-associated 
tumors. An individual having one or more of these risk 
factors has a higher probability of developing CEA-associ 
ated tumors than an individual Without these risk factor(s). 
These risk factors include, but are not limited to, age, sex, 
race, diet, history of previous disease, presence of precursor 
disease, genetic (i.e., hereditary) considerations, and envi 
ronmental exposure. Examples (i.e., categories) of high-risk 
groups are discussed beloW. 
Depending on the basis and context of assessment of high 
risk, the time frame Within Which probability of disease or 
tumor development, progression, and/or onset Would more 
likely than not occur Would vary. For instance, With breast, 
colorectal, and/or adenocarcinoma high risk patients in the 
adjuvant setting, the risk of occurrence is typically measured 
Within one to tWo years. For patients Who display precursor 
disease, the risk of occurrence can be measured in a longer 
time frame. For an individual Who is considered high risk 
due to, for example, genetic or hereditary considerations, the 
risk of occurrence can be measured in an even longer time 
frame, including the expected lifetime of the individual. 
An individual With “loW risk” is one Who is not consid 
ered “high risk”. 
“Adjuvant setting” refers to a clinical setting in Which an 
individual has had a history of CEA-associated disease, 
particularly CEA-associated tumors, and has been respon 
sive to therapy. The prior therapy can have included, but is 
not limited to, surgical resection, radiotherapy, and chemo 
therapy. As a result of this prior therapy, these individuals 
have no clinically measurable tumor. HoWever, because of 
their history of CEA-associated disease, these individuals 
are considered at risk of development of the disease. Treat 
ment or administration in the “adjuvant setting” refers to a 
subsequent mode of treatment. The degree of risk (i.e., 
Whether an individual in the adjuvant setting is considered 
“high risk” or “loW risk”) depends upon several factors, 
most usually the extent of disease When ?rst treated. 
As used herein, “adjuvant setting” is distinguished from 
an “adjuvant”, Which refers to a chemical or biological agent 
in a pharmaceutical preparation given in combination With 
an agent (such as an antibody, polynucleotide or polypep 
tide) to enhance its immunogenicity. Examples of adjuvants 
are described herein. 
A “neo-adjuvant setting” refers to the period after diag 
nosis but before initiation of treatment modalities other than 
administration of 3H1. For example, if an individual is 
diagnosed as having a CEA-associated tumor, such as col 
orectal, for Which surgery is indicated, administration of 
3H1 in a neo-adjuvant setting means that administration of 
3H1 commences before surgery. 
An “effective amount” is an amount suf?cient to effect 
bene?cial or desired clinical results. An effective amount can 
be administered in one or more administrations. For pur 
poses of this invention, an effective amount of 3H1 is an 
amount of 3H1 that is suf?cient to ameliorate, stabiliZe, or 
delay the development of the CEA-associated disease state, 
particularly CEA-associated tumors. Detection and mea 
surement of these indicators of ef?cacy are discussed beloW. 
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An “individual” is a vertebrate, preferably mammal, more 
preferably human. Mammals include, but are not limited to, 
farm animals, sport animals, and pets. 
EMBODIMENTS OF THE INVENTION 
In one embodiment, the invention provides methods 
delaying development of a CEA-associated tumor(s) in 
Which an effective amount of 3H1 is administered to an 
individual having a loW tumor burden. Examples of CEA 
associated tumors include, but are not limited to, carcinomas 
of the gastrointestinal tract (including colorectal cancer), 
other adenocarcinomas such as breast, lung (non small cell) 
cancer, biliary (including biliary tree) cancer and gyneco 
logical cancer. Methods of detecting CEA-associated tumors 
are knoWn in the art, including standard immunoassay 
techniques. As an example, CEA-associated tumors can be 
detected by standard immunohistologic examination of 
affected tissue, using, for example, 8019 as the primary 
antibody in an indirect immuno?uorescence assay. 
In one embodiment, the invention encompasses adminis 
tration of 3H1 to a high risk individual having a loW tumor 
burden. As discussed above, a high risk individual displays 
one or more risk factors that correlate With CEA-associated 
tumor development. High (i.e., increased) risk may be 
indicated, for example, on the basis of an individual’s 
genotype (for example, familial polyps), increased expres 
sion of tumor-associated genes or decreased expression of 
tumor suppressor genes, presence of precursor disease (such 
as polyps), a family history of CEA-associated cancer, a 
history of exposure to an environmental substance or form 
of radiation Which is knoWn or suspected of being carcino 
genic or teratogenic (particularly suspected of causing CEA 
associated tumors), exposure to a potentially carcinogenic 
pathogen such as a retrovirus, or a history of other types of 
cancer or other types of abnormal or unregulated tissue 
groWth. Also included as high risk are individuals suspected 
of having a CEA positive tumor based on a positive test for 
anti-CEA immunological reactivity. 
Because all risk factors for developing CEA-associated 
tumors are not knoWn, and the interplay among these factors 
(in terms of overall risk) are not fully understood, it is clear 
to one skilled in the art that individuals suitable for admin 
istration of 3H1 for purposes of this invention can have 
clinical features in common, and that individuals not falling 
clearly in the categories described above can nonetheless be 
considered suitable candidates for administration of 3H1. A 
skilled clinician can make an empirical determination 
Whether an individual is suitable for 3H1 treatment. For 
example, an individual With a familial (i.e., genetic) history 
of colorectal cancer could be considered “high risk”, even 
though no previous disease in this individual has been 
observed. In this context, administration of 3H1 to such an 
individual could result in delay of occurrence of disease, to 
the extent that the individual does not develop the disease 
Within his or her lifetime (or develops it later than Would 
have been expected). Another example is an individual Who 
is being treated using traditional modes of therapy, and Who 
is shoWing clinical responsiveness to the therapy (i.e., remis 
sion). Such an individual may be adjudged as “high risk”, 
even though the initial course of therapy is not yet com 
pleted, due to projection of clinical progress by the clinician 
and can be a suitable candidate for receiving 3H1 before 
completion of the initial therapy. The clinician, as one 
skilled in the art, has discretion to determine Whether 
treatment using 3H1 may be indicated. 
It is also evident that administration of 3H1 may be 
indicated even if an individual is not adjudged to be high risk 
(i.e., is “loW risk”) according to concurrent clinical risk 
assessment criteria. For instance, an individual Who has been 
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successfully treated and is not considered high risk (due, for 
example, to the lack of detectable invasive disease at the 
time of diagnosis) may nonetheless be a candidate for 
receiving 3H1 as a precautionary measure, especially con 
sidering the lack of contraindications and lack of undesirable 
side effects so far observed from 3H1. Thus, the risk of 
disease progression may be loWered even further by admin 
istration of 3H1. As another example, an individual may 
believe that he or she is at risk of disease development, and 
may decide that receiving 3H1 Would reduce this risk. Also 
suitable are individuals With supernormal levels of circulat 
ing CEA and/or supernormal levels of CEA expression. The 
circulating level of CEA can be determined by standard 
immunoassay (ELISA) techniques Which are commercially 
available (Hybritech). Levels of CEA expression can be 
determined by, for example, immunohistologic examination 
of affected tissue, using, for example, 8019 as the primary 
antibody in an indirect immuno?uoresce assay. 
As used herein, “supernormal” levels of CEA are greater 
than about 3 ng/ml. As is evident to one of skill in the art, 
the levels of circulating CEA can vary among laboratories 
(and depending upon the method and/or commercial kit 
used). Thus, supernormal levels of CEA can be greater than 
about 1 ng/ml to greater than about 5 ng/ml. 
In another embodiment of the present invention, 3H1 is 
administered to a high risk individual in the adjuvant setting. 
Factors typical as indicating individuals of high risk in the 
adjuvant setting are invasion by the tumor into neighboring 
tissues (i.e., extensive disease), and/or lymph node involve 
ment. Examples of high risk individuals in the adjuvant 
setting include, but are not limited to, (a) patients With Stage 
II or Stage IIIA adenocarcinoma of the lung With positive 
lymph nodes Who have had their tumor resected (these 
patients have a 60-80% relapse rate in the ?rst 2 years); (b) 
patients With breast cancer Who have positive lymph nodes 
in preferably at least 5, more preferably at least 10 (70-80% 
relapse rate in the ?rst 2 years for those With at least 10 
positive lymph nodes); and (c) patients With colon cancer 
With at least 4 positive lymph nodes (70-80% relapse rate in 
the ?rst 2 years). Another example of a high risk individual 
in the adjuvant setting is an individual having a gastric 
CEA-associated tumor that has been resected, including, but 
not limited to, pancreatic, gastric and biliary (including 
biliary tree) cancers. 
In another embodiment, 3H1 is administered in a neo 
adjuvant setting. It is understood that, for purposes of this 
invention, an individual in a neo-adjuvant setting has a loW 
tumor burden. 
Another example of an individual suitable for 3H1 
therapy as described in this invention is an individual With 
loW tumor burden. Thus, the present invention encompasses 
methods of treating CEA-associated tumors in an individual 
having a loW tumor burden comprising administering an 
effective amount of 3H1. As de?ned above, a “loW” tumor 
burden means that the disease is not considered advanced. 
For example, a loW tumor burden can be disease in partial 
or complete remission as adjudged by a clinical practitioner. 
“LoW” tumor burden can also arise by a reduction of tumor 
burden of advanced disease such that the extent of disease is 
no longer considered advanced. Other examples of loW 
tumor burden include disease contained to limited lymph 
node involvement. For these individuals, circulating CEA 
levels are usually less than or equal to about 50 ng/ml, 
preferably less than or equal to about 10 ng/ml, more 
preferably less than or equal to about 5 ng/ml, even more 
preferably less than or equal to about 3 ng/ml. An individual 
With a loW tumor burden can be further classi?ed as “high 
risk” or “loW risk,” depending on the individual’s clinical 
history. 
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The invention also includes methods of treatment using 
3H1 for individuals having residual disease, particularly 
minimal residual disease. “Residual” disease is any CEA 
associated disease, particularly CEA-associated tumor(s) 
remaining after therapy but Which is undetectable. Thus, 
“residual disease” refers to the likely presence of disease 
that can develop into detectable disease, and refers to a 
clinical prognosis and/or assumption made in an adjuvant 
setting. Depending on the type of CEA-associated tumor 
and, for example, the extent of disease upon diagnosis, an 
individual can be adjudged to have residual disease, even 
though no detectable disease is present. For example, an 
individual With resectable lung adenocarcinoma has residual 
disease after surgery (i.e., resection), even if an apparent 
complete remission has occurred. Similarly, an individual 
With colorectal cancer can have residual disease after che 
motherapy. Alternatively, an individual Who is currently 
undergoing therapy for a CEA-associated tumor also has 
“residual” disease. It is understood that, as used herein, 
“residual” disease does not include advanced disease. 
The invention also encompasses methods of reducing risk 
of occurrence of CEA-associated disease, particularly CEA 
associated tumors. In these methods, an effective amount of 
3H1 is administered to an individual at risk for developing 
CEA-associated disease. “Reducing risk of occurrence” 
means that the risk of occurrence and/or reoccurrence of 
CEA-associated disease is loWer in individuals receiving 
3H1 than those individuals (having the same risk of occur 
rence) Who do not. An individual “at risk” for developing 
CEA-associated disease can be high risk or loW risk, 
depending on the clinical and genetic history and status of 
the individual. 
The invention also encompasses methods of treatment of 
a CEA-associated tumor in an individual having a loW tumor 
burden and Who has a circulating level of CEA less than 
about 50 ng/ml. These methods entail administration of an 
effective amount of 3H1 to the individual. Preferably, the 
individual has a circulating level of CEA less than about 30 
ng/ml, more preferably less than about 25 ng/ml, still more 
preferably less than about 20 ng/ml, even more preferably 
less than about 15 ng/ml, even more preferably less than 
about 10 ng/ml, even more preferably less than about 5 
ng/ml. Methods of measuring levels of circulating CEA are 
knoWn in the art and some are described herein (see, e.g., 
Example 4). 
In another embodiment, the invention provides methods 
of treating a CEA-associated tumor, particularly adenocar 
cinoma, particularly adenocarcinoma of the colon and/or 
rectum, Which include administration of ?uorouracil (5-FU) 
With levamisole hydrochloride or leucovorin calcium, and 
3H1. We believe that 5-FU and levamisole or leucovorin 
may act synergistically With 3H1 to enhance the immune 
response. 5-FU With levamisole or leucovorin are treatments 
currently knoWn in the art, and for purposes of this inven 
tion, they are administered according to accepted clinical 
protocols (described in more detail beloW). 
For all of the above-described embodiments of the present 
invention, 3H1 can be prepared, administered, and moni 
tored as described in the folloWing sections. 
Preparation and Administration of Anti-idiotype Antibody 
3H1 
All embodiments of this invention entail administration of 
an effective amount of 3H1. 
3H1 can be obtained several Ways. 3H1 can be produced 
from the hybridoma ATCC No. HB12003 described herein. 
Methods of antibody isolation are Well knoWn in the art. See, 
for example, HarloW and Lane (1988) Antibodies: A Labo 
ralory Manual, Cold Spring Harbor Laboratory, NeW York, 
and Sambrook et al. (1989) Molecular Cloning: A Labora 












